Freising (ots) - Pieris AG announced today that Stephen Yoder, Chief Executive Officer, is scheduled to present at the 18th Annual BioCentury Future Leaders in the Biotech Industry Conference 2011, to be held Friday, April 15, 2011 at the Millennium Broadway Hotel & Conference Center in New York, New York. Mr. Yoder and Dr. Laurent Audoly, Chief Scientific Officer, ...
WMDO SA - World Medical Device Organization
Ecublens, Switzerland / Minneapolis, MN (ots) - WMDO (World Medical Device Organization), the leading global provider of innovative online training for medical device professionals, announced today that it has achieved its 100th online course. Excellent reviews from industry analysts, trade associations and users in recent months have enabled WMDO to leverage growing ...
Freising, Germany (ots) - Pieris AG announced today the upcoming presentation of new preclinical and interim Phase I clinical trial data for its PRS-050 Anticalin( program, currently under evaluation for the treatment of cancer. Dr. Laurent Audoly, Chief Scientific Officer of Pieris, will speak on Friday, February ...
European Society for Medical Oncology (ESMO)
Lugano (ots) - To coincide with World Cancer Day 2011, on 4 February, the Africa Oxford Cancer Foundation (AfrOx) and the European Society for Medical Oncology (ESMO) are working together to raise international awareness of the growing problem of cancer in Africa. AfrOx and ESMO are launching the 'Cancer in Africa: the Runaway Train' video, seeking to ...
DAKOMED - Dachverband Komplementärmedizin
Bern (ots) - Anthroposophic medicine, classic homoeopathy, neural-therapy, phytotherapy and traditional Chinese medicine will be paid for via the compulsory health insurance in Switzerland from 2012. This decision was taken by the Health Minister Didier Burkhalter on 13 January 2011. They will be included for a limited period of six years. During this period ...
St. Gallen Oncology Conferences (SONK)
St. Gallen (ots) - This bi-annual conference will highlight meaningful advances concerning treatment of Early Breast Cancer (EBC). The conference will build up on earlier diagnostic and therapeutic recommendations and thereafter provide written guidelines for the international community. Breast cancer specialists from all over the world are awaiting these new ...
WMDO SA - World Medical Device Organization
Washington D.C./Minneapolis, USA (ots) - MDMA (Medical Device Manufacturers Association), the leading national trade association for innovative and entrepreneurial medical technology companies and WMDO (World Medical Device Organization), the leading global provider of innovative online training for medical ...
San Francisco, USA and Freising, Germany (ots) - Takeda San Francisco (TSF) and Pieris AG have signed a drug discovery partnership agreement under which Pieris will apply its Anticalin® scaffold technology to deliver protein therapeutic candidates to Takeda, both companies announced today. The deal initially will focus on first-in-class drug discovery efforts ...
WMDO SA - World Medical Device Organization
Niva, Denmark/Ecublens (ots) - Medicoindustrien to Compliment its Live Training Program with WMDO's Online Courses Designed Specifically for Medical Device Professionals Medicoindustrien and WMDO (World Medical Device Organization), the leading global provider of innovative online training for medical ...
Lausanne (ots) - Debiopharm Group (Debiopharm), an independent specialist in global bio-pharmaceutical development in the field of oncology and regarding certain serious diseases, has announced the winner of the Prix Debiopharm Valais pourles Sciences de la Vie (Debiopharm Valais Life Sciences Prize). ...
Ittigen, Berne (ots) - Pevion Biotech AG today announced positive preliminary results from a Phase I study of PEV7, the first vaccine against recurrent vulvovaginal candidiasis (RVVC). Also known as chronic recurrent thrush, RVVC is a highly debilitating condition, which affects an estimated 3-6% of women ...
Lugano (ots) - New data presented at the ESMO Milan 2010 Congress show a better control of nausea and vomiting with palonosetron versus granisetron in patients undergoing cisplatin or anthracycline plus cyclophosphamide based regimens. Palonosetron superior efficacy is statistically significant in nausea control, following Highly Emetogenic Chemotherapy, in the ...
European Society for Medical Oncology (ESMO)
Lugano (ots) - Press releases will be issued during the Congress, on a daily basis. Please contact the ESMO Press Office at media@esmo.org if you would like to receive the full text of the press releases/abstracts in advance, available as of Wednesday, 6 October 2010 R. Bastian, DE Surgical ...
Zurich (ots) - Solianis Monitoring Ltd reaches another milestone testing their Multisensor Glucose Monitoring System for non-invasive continuous glucose monitoring in daily life The latest generation of Solianis' Multisensor Glucose Monitoring System with the final sensor configuration was tested in ...
Lugano (ots) - Helsinn's second-generation 5-HT3 RA Aloxi expands its presence in Asia through the Agreement signed with Mundipharma Helsinn Healthcare SA and Mundipharma International Corporation Ltd. announce the signature of a Distribution and Licensing Agreement for Helsinn's product palonosetron in Malesia, Philippines and Singapore. Aloxi® is a ...
Jena (ots) - In 2009 the Patents Court of the High Court, Chancery Division, decided that Occlutech's range of Figulla ASD and PFO occluders do not infringe the U.K. part of European Patent 0 808 138. AGA Medical decided to appeal against this decision. The U.K. Court of Appeal (civil division) in London announced its decision confirming that said Figulla ASD and PFO occluders do not infringe said patent. AGA asked ...
Freising-Weihenstephan (ots) - Pieris AG announced today the initiation of a Phase I clinical trial in cancer patients for its lead program, PRS-050, an anti-VEGF Anticalin. The trial is an open-label, dose-escalating evaluation of the compound's safety and tolerability in patients with solid tumors. ...
Freising-Weihenstephan (ots) - Pieris AG announced today that Laurent Audoly, Ph.D., has joined the company as Chief Scientific Officer, effective immediately. Dr. Audoly, most recently Biologics Research Site Lead at Merck & Co. Inc., brings both pharma and biotech experience, with extensive expertise in therapeutic protein drug development. "Laurent has an impressive track record of leading teams and ...
Geneva (ots) - PEARL I trial meets primary efficacy and safety endpoints / PregLem preparing for submission to the European Medicines Agency in 2010 PregLem, the European specialty biopharmaceutical company focused on women's reproductive medicine, announces positive Phase III data from its second pivotal study (PEARL I) for its lead product Esmya (ulipristal acetate), as an effective treatment for uterine ...
Freising-Weihenstephan (ots) - Novel Approach with PRS-110 Shows Dose-dependent Response in Cancer Model Pieris AG announced today preclinical data for its proprietary PRS-110 Anticalin" compound, which targets the c-Met receptor, demonstrating a dose-dependant reduction of tumor growth in a xenograft mouse model. The results provide an indication that an ...
Zürich (ots) - Solianis Monitoring AG is an important project partner in the development of REACTION, a professional service platform for doctors, caregivers and patients to improve the long term management of diabetes. The objective of the project is to improve glucose control in insulin requiring ...
Zug (ots) - The Swiss AmVac AG, a biopharmaceutical company located in Zug, has made significant advances in the manufacture and production of its vaccine candidate against RSV over the last few months. This vaccine candidate is based on the new Sendai vector technology for which Max-Planck-Innovations GmbH has acquired the exclusive licence. This technology, which has been developed by Prof. Wolfgang Neubert's ...
Zurich (ots) - Solianis Monitoring AG presents its Non-Invasive, Continuous Glucose Monitoring System at the 3rd International Conference on Advanced Technologies and Treatments for Diabetes (Basel, Switzerland, February 10-13, 2010). Dr. Andreas Caduff, PhD, Chief Technology Officer of Solianis, will present the concept of Solianis' proprietary ...
Saint-Prex, Switzerland (ots) - Results from a phase III pivotal study sub-analyses reported in European Urology show that prostate cancer patients who received Firmagon® (degarelix) in the study have a statistically significant greater probability of PSA (prostate-specific-antigen) recurrence-free survival ...
Aachen, Germany (ots) - The European Federation of Chapters of the International Association for the Study of pain (EFIC) and the pharmaceutical company Grunenthal awarded the EFIC-Grunenthal Grant to five young European scientists. The grant will provide financial support for their future projects in ...
Zug (ots) - The Swiss biopharmaceuticals company AmVac AG in Zug has joined forces with the long-term strategic investor V+ GmbH & Co Fonds 2 KG. The private equity company based in Dresden has invested CHF 1,500,000 in AmVac AG since the first half of 2009. Last week V+ GmbH & Co Fonds 2 KG announced their intention of acquiring further shares in AmVac AG to the sum of CHF 3,000,000.00. Michael Vogel, spokesman of the investment board: "We agree with boosting ...
Munich, Germany (ots) - An educational programme available on DVD is launched today, on World Osteoporosis Day, bringing together the glamorous world of ballroom dance with the serious nature of disease management. Sponsored by DAIICHI SANKYO EUROPE and endorsed by the International Osteoporosis Foundation, ...
Freising-Weihenstephan, Germany (ots) - Pieris AG, the biopharmaceutical company developing Anticalins as a novel class of targeted human protein therapeutics, today reported continued progress in development of its lead therapeutic program for the clinic. Under its manufacturing agreement with Wacker Biotech ...
Zurich (ots) - - Indication: Health Tips from EAACI can be downloaded free of charge as a pdf-file under: http://www.presseportal.ch/de/pm/100018272/?langid=2 - EAACI, the largest European organisation in the field of allergy, immunology and asthma, today hosted a specialist forum on "Swine-flu - a threat for asthmatics? What people ...
Lugano/Berlin, Germany (ots) - Single dose palonosetron achieves optimal control of acute emesis in patients receiving multiday-high dose chemotherapy before autologous stem cell transplantation. The addition of a second dose of palonosetron after 48 hours significantly reduces the detrimental impact of ...